What might be in our future...7 May 2024 18:09
OK so I've banged on about EF...but this might help you see why...these are his current positions and so company highlights which might indicate what sort of deals or investors we might hope to see.
Eliot Forster has been NE Director for Immatics NV (NASDAQ) since 2021and the following is from their March 2024 Y/E Results
First clinical data updates for Immatics’ next-generation TCR Bispecifics, TCER® IMA401 (MAGEA4/8) and TCER® IMA402 (PRAME), from ongoing Phase 1 dose escalation trials planned for 2H 2024; updates to include details on safety, pharmacokinetics and initial anti-tumor activity
In May 2023, Bristol Myers Squibb exercised first opt-in into the autologous cell therapy collaboration ($15 million option fee received) and made a $35 million equity investment in July 2023
In September 2023, Immatics and Moderna announced a strategic multi-platform collaboration to develop innovative oncology therapeutics; Immatics received $120 million upfront payment, and the total deal volume could exceed $1.7 billion
$201.5 million public offering completed on January 22, 2024
Eliot Forster has been Chairperson for Ochre Bio since May 2023
22 April 2024 — Ochre Bio today announced a partnership with Boehringer Ingelheim focused on the discovery and development of novel, first-in-class regenerative treatments for chronic liver diseases. In this multi-year, multi-target collaboration, Ochre Bio will receive up to USD 35 million in upfront and near-term research-based milestone payments. Ochre may also receive milestones for clinical, regulatory, and commercial success as well as tiered royalties with an overall deal value with the potential to exceed USD 1 billion.
Eliot Forster has been Chairman of Protalix Therapeutics since Sept 2023
On May 10, 2023, the Company announced that the U.S. Food and Drug Administration (FDA) approved Elfabrio in the United States for the treatment of adult patients with Fabry disease.
The FDA approval triggered a $20.0 million milestone payment from Chiesi. In addition, the Company generated $17.5 million from sales of Elfabrio to Chiesi during 2023 post-regulatory approval, as Chiesi is building its inventory and recruiting commercial patients in the United States and Europe.
Eliot Forster is also Chair of the Board of Tessellate Bio
Tessellate Bio was founded to develop precision oncology approaches to treat cancers with high unmet need. And their main investor is BGV has a broad investor base comprising private equity/wealth managers, pension funds, academic institutions, regional development funds and private investors. Strategic investors include Eli Lilly and Company, Novo Holdings and Bristol Myers Squibb. BGV co-founder and lead investor in Acerta which was sold to Astra Zenica in 2016 for up to $7 billion.
Cont...
Sign In
Follow the stocks
